Citation

  • Authors: Boudria, A., Abou Faycal, C., Jia, T., Gout, S., Keramidas, M., Didier, C., Lemaitre, N., Manet, S., Coll, J. L., Toffart, A. C., Moro-Sibilot, D., Albiges-Rizo, C., Josserand, V., Faurobert, E., Brambilla, C., Brambilla, E., Gazzeri, S., Eymin, B.
  • Year: 2018
  • Journal: Oncogene
  • Applications: in vivo / siRNA / in vivo-jetPEI-Gal
  • Cell type: H358
    Description: Human bronchioalveolar carcinoma; non-small cell lung carcinoma cells

Method

H358 cells were allowed to form tumors for 3–4 weeks. When tumor volumes reached 30– 40 mm3 , mice were alternatively subcutaneously- or intraperitoneally-injected 4 times a week with either mismatch siRNA as a control or VEGF165b siRNA. Once a week, siRNAs were combined with either bevacizumab (7.5 mg/kg) or PBS as a control. Transfection of siRNA was performed using in vivo-jetPEI-Gal.

Abstract

Vascular endothelial growth factor-A (VEGF-A) is highly subjected to alternative pre-mRNA splicing that generates several splice variants. The VEGFxxx and VEGFxxxb families encode splice variants of VEGF-A that differ only at the level of six amino acids in their C-terminal part. The expression level of VEGFxxx splice variants and their function as pro-angiogenic factors during tumor neo-angiogenesis have been well-described. The role of VEGFxxxb isoforms is less well known, but they have been shown to inhibit VEGFxxx-mediated angiogenesis, while being partial or weak activators of VEGFR receptors in endothelial cells. On the opposite, their role on tumor cells expressing VEGFRs at their surface remains largely unknown. In this study, we find elevated levels of VEGF165b, the main VEGFxxxb isoform, in 36% of non-small cell lung carcinoma (NSCLC), mainly lung adenocarcinoma (46%), and show that a high VEGF165b/VEGF165 ratio correlates with the presence of lymph node metastases. At the molecular level, we demonstrate that VEGF165b stimulates proliferation and invasiveness of two lung tumor cell lines through a VEGFR/beta1 integrin loop. We further provide evidence that the isoform-specific knockdown of VEGF165b reduces tumor growth, demonstrating a tumor-promoting autocrine role for VEGF165b in lung cancer cells. Importantly, we show that bevacizumab, an anti-angiogenic compound used for the treatment of lung adenocarcinoma patients, increases the expression of VEGF165b and activates the invasive VEGFR/beta1 integrin loop. Overall, these data highlight an unexpected role of the VEGF165b splice variant in the progression of lung tumors and their response to anti-angiogenic therapies.

Pubmed